Caredx Stock Price, News & Analysis

CareDx, Inc. (CDNA) announced the publication of results from the ADMIRAL study, demonstrating that its AlloSure® Kidney test effectively detects both clinical and subclinical allograft injuries in kidney transplant patients. The multicenter study, which monitored 1,092 patients, showed a 62% improvement over standard serum creatinine in identifying rejections. AlloSure correlated with a 271% increased risk of donor-specific antibody formation and can predict long-term graft survival. These findings highlight AlloSure's potential to transform transplant care and enhance patient outcomes.

CareDx, Inc. (Nasdaq: CDNA) announced collaborations with three leading biopharmaceutical companies to incorporate its AlloCell surveillance solutions in ongoing CAR T-cell therapy clinical studies. AlloCell serves as a next-generation sequencing tool to monitor the expansion and persistence of allogeneic cell therapies in cancer patients. The potential market for AlloCell in oncology is estimated over $5.5 billion. This initiative reflects CareDx's commitment to advancing cell therapy research and improving patient outcomes.

CareDx, Inc. (Nasdaq: CDNA) reported preliminary financial results for Q4 and full year 2021, showcasing significant growth. Q4 revenue is projected between $78.6 million and $79.0 million, up 34% to 35% year-over-year, with over 41,900 tests conducted. Full year revenue is anticipated to be between $295.7 million and $296.1 million, reflecting a 54% increase from 2020. The company achieved CLIA validation for AlloMap Kidney and completed five acquisitions, strengthening its market position. Cash reserves stood at $348 million as of December 31, 2021.

CareDx, Inc. announced significant findings from the ALARM study published in The Journal of Heart and Lung Transplantation. The study validates the efficacy of AlloSure Lung for non-invasive monitoring of lung transplant recipients during the COVID-19 pandemic. Conducted across four centers, it showed that AlloSure can detect acute rejection and infection with a sensitivity of 73.9% and specificity of 87.7%. Notably, using this method reduced invasive biopsies by 83%. These advancements highlight a safer and effective approach for transplant patient surveillance.

CareDx, Inc. (CDNA) announced the successful completion of CLIA validation for AlloMap Kidney, a blood-based gene expression classifier identifying immune quiescence, crucial for assessing rejection risk and allograft health. The clinical validation indicates AlloMap Kidney can differentiate between rejection types and immune quiescence, achieving a combined area under the curve (AUC) of 0.894. This validation is a significant step toward commercializing the KidneyCare multimodality solution, enhancing monitoring for kidney transplant health.

CareDx Acquires The Transplant Pharmacy to Enhance Support for Organ Transplant Patients. Located in Flowood, Mississippi, The Transplant Pharmacy specializes in individualized medication management services for transplant patients across the U.S. This acquisition strengthens CareDx’s connection with patients and expands its portfolio, which includes AlloCare™, Transplant Hero™, and MedActionPlan. CEO Reg Seeto emphasized the importance of medication adherence in improving patient outcomes. The acquisition aims to deliver personalized pharmaceutical care, ultimately benefiting organ transplant recipients.

CareDx, Inc. (Nasdaq: CDNA) has partnered with the International Society for Heart and Lung Transplantation (ISHLT) to introduce the Innovation Challenge Award. This initiative aims to promote research on the clinical utility of donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling (GEP) methodologies in heart and lung transplants. Applications are open until January 31, 2022, with finalists presenting at the ISHLT 2022 Annual Meeting in April. Dr. Sham Dholakia expressed the importance of these non-invasive techniques for improving long-term transplant patient outcomes.

CareDx, Inc. has initiated the ALAMO registry, enrolling 1,000 lung transplant patients across the U.S. to enhance clinical decision-making. This study aims to evaluate LungCare's capability to detect transplant infections and rejections. Utilizing tests like AlloSure, AlloMap, and AlloID, the registry will track outcomes over three years, focusing on survival rates and severe infections. The development of multimodality diagnostics is expected to provide significant benefits in managing lung transplant recipients, potentially reducing the need for invasive biopsies.

CareDx, Inc. has partnered with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) to utilize their pediatric patient registry for a long-term outcomes study of AlloSure, a donor-derived cell-free DNA service aimed at improving organ transplant care in pediatric kidney patients. The study will track data for five years or until its conclusion, validating the utility of dd-cfDNA testing in managing long-term patient outcomes. This collaboration highlights CareDx's commitment to providing innovative solutions for pediatric transplant patients.